<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014429</url>
  </required_header>
  <id_info>
    <org_study_id>PLKA-937-001</org_study_id>
    <nct_id>NCT01014429</nct_id>
  </id_info>
  <brief_title>Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I Dose Escalation Study of NMS-1286937 Administered to Adult Patients With Advanced/Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nerviano Medical Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nerviano Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of NMS-1286937, a
      polo-like-kinase 1 inhibitor, in patients with advanced metastatic solid tumor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) and first cycle dose limiting toxicities (DLTs)</measure>
    <time_frame>Cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics: plasma concentration at different times after dosing, area under the curve (AUC), maximum plasma concentration (Cmax), clearance (CL), volume of distribution, half-life (tÂ½)</measure>
    <time_frame>Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacodynamics: biomarkers modulation in skin and/or tumor samples of consenting patients</measure>
    <time_frame>Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NMS-1286937</intervention_name>
    <description>Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced/metastatic solid tumors, for which no effective standard therapy exist

          -  Adult patients (age &gt;/= 18)

          -  ECOG performance status (PS) 0 or 1

          -  Life expectancy of at least 3 months

          -  Adequate renal, liver function and bone marrow reserve

          -  Prior cancer therapy allowed, with max 4 regimens of chemotherapy. Washout: at least 4
             wks (6 wks for nitrosoureas, mitomycin C and liposomal doxorubicin) and all toxicities
             recovered to CTC Grade &lt;/=1

          -  Prior radiotherapy allowed if no more than 25% of BM reserve irradiated

          -  Women and men of child producing potential should agree to use effective contraception

          -  Capability to swallow capsules intact

        Exclusion Criteria:

          -  Known uncontrolled/symptomatic brain metastases

          -  Currently active second malignancy

          -  Major surgery in the last 4 wks

          -  Any of the following in the past 6 months: myocardial infarction, unstable angina,
             coronary/peripheral artery bypass graft, symptomatic congestive heart failure,
             cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein
             thrombosis

          -  Pregnancy or breast-feeding women

          -  Known active infections

          -  History of drug allergic reactions

          -  Gastrointestinal disease or other malabsorption syndromes that would impact on drug
             absorption.

          -  Documented gastrointestinal ulcer

          -  Other severe concurrent acute or chronic medical or psychiatric condition that could
             compromise protocol objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariangela Mariani, Biol Sci D</last_name>
    <role>Study Director</role>
    <affiliation>Nerviano Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Adele Pacciarini, Biol Sci D</last_name>
    <role>Study Director</role>
    <affiliation>Nerviano Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Glen J Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arizona TGen Clinical Reserch Services at Scottsdale Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona TGen Clinical Research Services at Scottsdale Heathcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2009</study_first_posted>
  <last_update_submitted>September 6, 2012</last_update_submitted>
  <last_update_submitted_qc>September 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I dose escalation study</keyword>
  <keyword>Advanced or metastatic solid tumors</keyword>
  <keyword>PLK 1 inhibitor</keyword>
  <keyword>Adult patients</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

